Experience

XR Therapeutics

• United Kingdom
• Mental Health Care
• 1 - 100 Employee

• Chairman

  • Apr 2021 - Present



Ant Workshop Ltd

• United Kingdom
• Computer Games
• 1 - 100 Employee

• Chairman

  • Apr 2018 - Present



Fine Organics Limited

• United Kingdom
• Chemical Manufacturing
• 1 - 100 Employee

• CEO

  • Nov 2015 - Jun 2017

  Board member responsible for monthly reporting, issue management and strategy development. Responsible for all P&L activities of the business, including “right sizing” the operations team to match the earning potential of the facility. Improved business development and commercial management processes to strengthen the portfolio pipeline. To lead contract negotiation and ensure product pricing and margins are consistent with the business strategy whilst minimising commercial risk for the… Show more Board member responsible for monthly reporting, issue management and strategy development. Responsible for all P&L activities of the business, including “right sizing” the operations team to match the earning potential of the facility. Improved business development and commercial management processes to strengthen the portfolio pipeline. To lead contract negotiation and ensure product pricing and margins are consistent with the business strategy whilst minimising commercial risk for the business. Drive operational output and supply chain management in the business by improving the review process and ensuring that KPI's are relevant and representative of performance. Responsible for compliance improvement and the management of occupational health issues and for Board member interaction with the HSE. Show less Board member responsible for monthly reporting, issue management and strategy development. Responsible for all P&L activities of the business, including “right sizing” the operations team to match the earning potential of the facility. Improved business development and commercial management processes to strengthen the portfolio pipeline. To lead contract negotiation and ensure product pricing and margins are consistent with the business strategy whilst minimising commercial risk for the… Show more Board member responsible for monthly reporting, issue management and strategy development. Responsible for all P&L activities of the business, including “right sizing” the operations team to match the earning potential of the facility. Improved business development and commercial management processes to strengthen the portfolio pipeline. To lead contract negotiation and ensure product pricing and margins are consistent with the business strategy whilst minimising commercial risk for the business. Drive operational output and supply chain management in the business by improving the review process and ensuring that KPI's are relevant and representative of performance. Responsible for compliance improvement and the management of occupational health issues and for Board member interaction with the HSE. Show less



Aesica Pharmaceuticals Ltd

• United Kingdom
• Pharmaceutical Manufacturing
• 100 - 200 Employee

• Managing Director

  • May 2014 - Oct 2015

  Responsible for all P&L activities in Aesica’s API Business Unit including business development, commercial management, operational output and supply chain management. The role also involves strategic planning and assessment of potential acquisition targets that complement the expansion and growth strategy.

• Chief Operating Officer

  • Jun 2013 - May 2014

  Responsible for all operational activities within the Aesica group across UK, Germany and Italy. The scope of the role was end to end operations from procurement, supply chain delivery, operational output, technical improvement and supply chain export. Management of a team of approximately 1300 employees and an expense budget of £70m.

• Corporate Manufacturing and Compliance Director

  • Jan 2011 - Jun 2013

  Responsible for value creation and continuous improvement, IT, capital spend management, corporate compliance policy and IP and group EHS improvement.

• UK General Manager

  • Jan 2010 - Jan 2011

  Director of manufacturing, responsible for all operational activities on Aesica’s three manufacturing sites in Queenborough, Cramlington and Ponders End. Responsible for the UK P&L activities covering sales planning, supply chain, manufacturing and dispatch.

• Technical Director

  • 2008 - 2010

  Responsible for establishing and growing the Aesica Technical Team as an independent profit centre. Growing the team from a few support chemists to an independent team of around 25 FTE’s undertaking contract work for various start-up and mid-size pharmaceutical companies. Turnover of the team at year end 2010 approximately £1m.

• Quality Director

  • 2007 - 2008

  Director responsible for all Quality and Regulatory operations across API and formulated product manufacture. Key member of the Queenborough transition team responsible for the integration of Abbott products and marketing authorisations into the Aesica business.

• Operations Director

  • 2006 - 2007

  Director of API manufacture responsible for all manufacturing activities on both Aesica manufacturing sites in Cramlington and Ponders End (London). Responsible for the integration of the MSD Ponders End site into Aesica business and the completion of transition plan activities.

• Compliance Director

  • 2004 - 2006

  Director responsible for HS&E, QA and QC, management of 18 personnel, company policy setting, drug master file submissions and site compliance. Member of the management buy-out team that established Aesica in 2004.



BASF

• Germany
• Chemical Manufacturing
• 700 & Above Employee

• Quality and Compliance Manager

  • 2000 - 2004

  Responsible for HS&E, QA and QC, management of 18 personnel, policy setting, drug master file submissions and site compliance. Responsible for HS&E, QA and QC, management of 18 personnel, policy setting, drug master file submissions and site compliance.



Boots / Knoll Pharmaceuticals

• Nottingham, United Kingdom

• Scientist

  • 1992 - 2000

  Analysis of finished dosage forms and API’s for QC release. Analysis of finished dosage forms and API’s for QC release.